TY - JOUR
T1 - Chimeric antigen receptor T-cell therapy
AU - Ogba, Ndiya
AU - Arwood, Nicole M.
AU - Bartlett, Nancy L.
AU - Bloom, Mara
AU - Brown, Patrick
AU - Brown, Christine
AU - Budde, Elizabeth Lihua
AU - Carlson, Robert
AU - Farnia, Stephanie
AU - Fry, Terry J.
AU - Garber, Morgan
AU - Gardner, Rebecca A.
AU - Gurschick, Lauren
AU - Kropf, Patricia
AU - Reitan, Jeff J.
AU - Sauter, Craig
AU - Shah, Bijal
AU - Shpall, Elizabeth J.
AU - Rosen, Steven T.
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
AB - Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
UR - http://www.scopus.com/inward/record.url?scp=85053000143&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0073
DO - 10.6004/jnccn.2018.0073
M3 - Article
C2 - 30181421
AN - SCOPUS:85053000143
SN - 1540-1405
VL - 16
SP - 1093
EP - 1106
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -